» Articles » PMID: 32820610

Severe Neurological Crisis in Adult Patients with Tyrosinemia Type 1

Overview
Specialty Neurology
Date 2020 Aug 22
PMID 32820610
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

We report six adult patients with Tyrosinaemia type 1 (HT-1) who presented with recurrent porphyria-like neurological crises after discontinuation/interruption of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) treatment. The crises were life-threatening for some of the patients, with respiratory muscle paralysis requiring ventilatory support, hemodynamic disturbance due to autonomic changes requiring resuscitation, acute progressive ascending motor neuropathy causing profound impairment, recurrent seizures, and neuropathic pain. Our patients' porphyria-like presentations were variably misdiagnosed, with delay to diagnosis resulting in more severe recurrent attacks. We report the first series of neurological crises in adult patients with HT-1. These crises, which may be fatal, can be prevented and treated effectively with neurologist/physician awareness and patient education.

Citing Articles

mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model.

Cacicedo M, Weinl-Tenbruck C, Frank D, Wirsching S, Straub B, Hauke J Mol Ther Methods Clin Dev. 2022; 26:294-308.

PMID: 35949297 PMC: 9357842. DOI: 10.1016/j.omtm.2022.07.006.


Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

Tang Y, Kong Y Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021; 50(4):514-523.

PMID: 34704422 PMC: 8777462. DOI: 10.3724/zdxbyxb-2021-0255.


Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review.

Daou K, Barhoumi A, Bassyouni A, Karam P Front Pediatr. 2021; 9:698577.

PMID: 34422723 PMC: 8377248. DOI: 10.3389/fped.2021.698577.


Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.

Colemonts-Vroninks H, Neuckermans J, Marcelis L, Claes P, Branson S, Casimir G Genes (Basel). 2020; 12(1).

PMID: 33375092 PMC: 7822164. DOI: 10.3390/genes12010003.

References
1.
Schlump J, Perot C, Ketteler K, Schiff M, Mayatepek E, Wendel U . Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis. 2008; 31 Suppl 2:S223-5. DOI: 10.1007/s10545-008-0807-z. View

2.
Rank J, Pascual-Leone A, Payne W, Glock M, Freese D, Sharp H . Hematin therapy for the neurologic crisis of tyrosinemia. J Pediatr. 1991; 118(1):136-9. DOI: 10.1016/s0022-3476(05)81867-0. View

3.
Lindstedt S, Holme E, Lock E, Hjalmarson O, Strandvik B . Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992; 340(8823):813-7. DOI: 10.1016/0140-6736(92)92685-9. View

4.
Kalkanoglu H, Coskun T . Neurological crisis mimicking acute pancreatitis in tyrosinemia type I. Turk J Pediatr. 2000; 41(4):501-4. View

5.
Lindblad B, Lindstedt S, Steen G . On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A. 1977; 74(10):4641-5. PMC: 432003. DOI: 10.1073/pnas.74.10.4641. View